Amundi Index Solutions - Amundi MSCI China Tech ESG Screened UCITS ETF Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Amundi Index Solutions - Amundi MSCI China Tech ESG Screened UCITS ETF's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Capital Markets Industry Growth | 15.2% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Earnings Update | n/a |
Recent past performance updates
No updates
Recent updates
No updates
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Amundi Index Solutions - Amundi MSCI China Tech ESG Screened UCITS ETF has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
Show sectionRevenue & Expenses Breakdown
How Amundi Index Solutions - Amundi MSCI China Tech ESG Screened UCITS ETF makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|
Quality Earnings: Insufficient data to determine if 18MG has high quality earnings.
Growing Profit Margin: Insufficient data to determine if 18MG's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if 18MG's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare 18MG's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.
Earnings vs Industry: Insufficient data to determine if 18MG's earnings growth over the past year exceeded the Capital Markets industry average.
Return on Equity
High ROE: 18MG has a negative Return on Equity (0%), as it is currently unprofitable.